Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort.
* Context.--Following the validation of a multicolor flow cytometry (MFC) assay for measurable residual disease (MRD) in acute myeloid leukemia (AML), this study examines its clinical applicability. Objective.--To evaluate the practicality and performance of MFC-based MRD detection in AML. Design.--...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 150; no. 1; pp. 72 - 81 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Jan2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=191144600&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 191144600 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Jan2026 vid: 150 iid: 1 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 191144600 191144600 191144600 10.5858/arpa.2025-0053-OA 191144600 ppf: 72 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient Cohort. aug: au: Wang, Sa A. Li, Shaoying Wang, Wei Xu, Jie Thakral, Beenu Hu, Shimin Ok, Chi Young Jia, Fuli Jorgensen, Jeffrey L. Medeiros, L. Jeffrey Ravandi, Farhad Short, Nicholas J. Loghavi, Sanam affil: Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston sug: subj: Leukemia, Myeloid, Acute Prognosis Neoplasm Recurrence, Local Risk Factors Disease Remission Diagnosis Flow Cytometry Methods Instrument Validation Risk Assessment Human Middle Age Aged Aged, 80 and Over Male Female Validation Studies Prospective Studies Genetics Survival Analysis Bone Marrow Examination Descriptive Statistics Hematopoiesis Disease-Free Survival Overall Survival False Negative Results Sequence Analysis Reverse Transcriptase Polymerase Chain Reaction Fisher's Exact Test T-Tests Comparative Studies Kaplan-Meier Estimator Data Analysis Software Middle Aged: 45-64 years Aged: 65+ years Aged, 80 & over Male Female ab: * Context.--Following the validation of a multicolor flow cytometry (MFC) assay for measurable residual disease (MRD) in acute myeloid leukemia (AML), this study examines its clinical applicability. Objective.--To evaluate the practicality and performance of MFC-based MRD detection in AML. Design.--Prospectively assessed AML MRD MFC in unselected AML patients achieving morphologic remission with follow-up studies, molecular genetics, and survival data. Results.--Among 379 patient bone marrow samples in this cohort, an interpretable result was obtained in 359 (95%). A total of 57 of the 359 cases (16%) were positive for MRD, and the most frequently observed immunophenotype was CD34-/CD117+ myeloid (n = 46; 81%), followed by CD34-/CD117+ myeloid (n = 8; 14%) and monocytic (n = 3; 5%). Of 57 MRD1 cases, 6 (11%) had no leukemia-associated immunophenotypes available, and 16 of 51 (31%) with leukemia- associated immunophenotype for comparison exhibited significant immunophenotypic drift/switch, highlighting the importance of the "deviation from normal" approach. The remaining 302 cases were MRD negative; among these, 21 (7%) displayed a preleukemic immunophenotype that was associated with persistent clonal hematopoiesis in 18 patients (86%). A positive MFC result was strongly associated with subsequent follow-up positive MRD (41 of 45 [91%] versus 14 of 240 [6%], P < .01), morphologic relapse (42 of 55 [76%] versus 48 of 301 [16%], P < .01), an inferior overall survival (12.5 months versus not reached, P < .01), and leukemia-free survival (6.5 months versus not reached, P < .01). Among MRD-negative patients, a preleukemic phenotype was associated with a shorter overall survival (P = .03), but not leukemia-free survival (P = .16). Conclusions.--Our study provides data-driven technical insights for laboratories considering MFC AML MRD implementation and offers strong evidence supporting the utility of MRD assessment by MFC in patients with AML undergoing various stages of treatment and surveillance. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|